Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.352 5-Year IF: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v18.i1-2.50
pages 37-45

HER-2/neu Oncogenic Protein: Issues in Vaccine Development

Mary L. Disis
Division of Oncology, Box 356527, University of Washington, Seattle, WA 98195-6527
Martin A. Cheever
Division of Oncology, Box 356527, University of Washington, Seattle, WA 98195-6527


Vaccine studies using whole tumor cells or heterogeneous mixtures of tumor antigens provide intriguing evidence that cancer vaccines might be effective. Now it is possible to test vaccines composed of well-characterized proteins and peptides. Testing vaccine formulations composed of known and defined antigens will allow a more precise determination as to why vaccines work when they work, and why they do not work when they fail. The demonstration that human malignancy is immunogenic and the definition of human tumor antigens has set the stage for a new generation of cancer vaccines directly targeting immunogenic cancer-related peptides and proteins. Many newly defined tumor antigens are self proteins. As an example, screening existent immunity in human melanoma has identified responses to nonmutated self proteins: MAGE, MART, gplOO, and tyrosinase. Tolerance to self antigens now emerges as a possible mechanism of tumor immune escape. A new puzzle has emerged for tumor immunologists to solve; how to harness immunity to "self" tumor antigens for cancer therapeutics.

Articles with similar content:

SV40-lnduced Immortalization of Human Cells
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 4
Roger R. Redder, Tracy Bryan
Clinical Translation of Peptide-Based Vaccine Trials: The HER-2/neu Model
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Keith L. Knutson, Douglas G. McNeel, Mary L. Disis, Donna Davis, Kathy Schiffman
The Microbiome of Oral Cancer
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Edward J. Shillitoe
Human Immunodeficiency Virus Type 1 Pharmacogenomics in Clinical Practice: Relevance of HIV-1 Drug Resistance Testing (Part 1)
Journal of Environmental Pathology, Toxicology and Oncology, Vol.22, 2003, issue 3
Nancy G. Klimas, Margaret Marchette, Charles Mitchell, Eduardo Meneses Sierra, Alejandro Isava, Dushyantha Jayaweera, Enriqueta Nunez, J. Brian Page, Gwendolyn Scott, Roberto Patarca, Nelson J. Rodriguez, Mary Ann Fletcher, Delia Rivera, Michael Kolber, Mirtha M. Sanabia, Rafael Campo, Cindy W. Mask, Jose Moreno, Michael Alter, Ricardo Vallejo, Catherine Boulanger
Immortalization of Human Cells and Its Mechanisms
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 1-2
Koichiro Mihara, Kazuo Fushimi, Masayoshi Namba